Michael David Guttenplan, MD in Tempe, AZ - Medicare Otolaryngology

Michael David Guttenplan, MD is a medicare enrolled "Otolaryngology" physician in Tempe, Arizona. He went to Perelman School Of Med At The University Of Pennsylvania and graduated in 1985 and has 39 years of diverse experience with area of expertise as Otolaryngology. He is a member of the group practice District Medical Group Inc and his current practice location is 1492 S Mill Ave, Suite 301, Tempe, Arizona. You can reach out to his office (for appointments etc.) via phone at (480) 894-5550.

Michael David Guttenplan is licensed to practice in Arizona (license number 48133) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1821075391.

Contact Information

	Michael David Guttenplan, MD
	1492 S Mill Ave, Suite 301, Tempe, AZ 85281
	(480) 894-5550
	(780) 894-9469

Physician's Profile

Full Name	Michael David Guttenplan
Gender	Male
Speciality	Otolaryngology
Experience	39 Years
Location	1492 S Mill Ave, Tempe, Arizona
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Michael David Guttenplan attended and graduated from Perelman School Of Med At The University Of Pennsylvania in 1985

NPI Data:

NPI Number: 1821075391
Provider Enumeration Date: 12/27/2005
Last Update Date: 02/04/2014

Medicare PECOS Information:

PECOS PAC ID: 3678484664
Enrollment ID: I20140721002270

Medical Identifiers

Medical identifiers for Michael David Guttenplan such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1821075391	NPI	-	NPPES
8H0731	Other	TX	BCBS
114231102	Other	TX	FIRSTCARE/SWLIFEHEALTH
8774426	Medicaid	AZ
040017696	Other	TX	RR MEDICARE

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Y00000X	Otolaryngology	H7751 (Texas)	Secondary
207Y00000X	Otolaryngology	48133 (Arizona)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Valleywise Health Medical Center	Phoenix, AZ	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
District Medical Group Inc	7315086691	356

News Archive

Study provides insights into molecular mechanisms of ZIKV infection

Zika virus (ZIKV) interferes with the cellular machinery controlling cell division and alters the expression of hundreds of genes guiding the formation and development of neurons and astrocytes, according to findings released on January 23rd 2017 at Scientific Reports.

Despite international guidelines, wide variations exist in breast cancer care

A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.

Researchers highlight how biomarkers after ACL reconstruction may signal severity of PTOA later in life

A majority of Anterior Cruciate Ligament (ACL) reconstruction patients develop a condition known as posttraumatic osteoarthritis (PTOA) within 15 years of surgery, which can be debilitating and limit activity. Researchers presenting their work at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Diego are highlighting how a set of biomarkers on the day of surgery may explain why some individuals have worse PTOA than others after two years.

UCB, Emerald BioStructures expand collaboration for structure-based drug discovery

Emerald BioStructures, a leading provider of fragment-based drug discovery services, announced today that it has successfully achieved the second milestone in its collaboration with UCB on the structure-based discovery of small molecule modulators of undisclosed targets.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Michael David Guttenplan allows following entities to bill medicare on his behalf.

Entity Name	District Medical Group Inc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1336472448 PECOS PAC ID: 7315086691 Enrollment ID: O20091125000583

News Archive

Study provides insights into molecular mechanisms of ZIKV infection

Despite international guidelines, wide variations exist in breast cancer care

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

Researchers highlight how biomarkers after ACL reconstruction may signal severity of PTOA later in life

UCB, Emerald BioStructures expand collaboration for structure-based drug discovery

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Michael David Guttenplan is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Michael David Guttenplan, MD 1492 S Mill Ave, Suite 301, Tempe, AZ 85281 Ph: (480) 894-5550	Michael David Guttenplan, MD 1492 S Mill Ave, Suite 301, Tempe, AZ 85281 Ph: (480) 894-5550

News Archive

Study provides insights into molecular mechanisms of ZIKV infection

Despite international guidelines, wide variations exist in breast cancer care

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

Researchers highlight how biomarkers after ACL reconstruction may signal severity of PTOA later in life

UCB, Emerald BioStructures expand collaboration for structure-based drug discovery

Otolaryngology Doctors in Tempe, AZ

Kristin Schad Nelson, DO Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1492 S Mill Ave, Suite 301, Tempe, AZ 85281 Phone: 480-894-5550 Fax: 480-894-9469
Thad Edward Bartell, MD Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 2131 E Southern Avenue, Tempe, AZ 85282 Phone: 480-820-1200 Fax: 480-820-5743
Dr. David B Mendelson, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1492 S Mill Ave Ste 301, Tempe, AZ 85281 Phone: 480-894-5550 Fax: 480-894-9469
Keith E Mcreynolds, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1460 E Colt Road, Tempe, AZ 85284 Phone: 480-227-0500
Robert A Miller, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1492 S. Mill Ave, Suite 301, Tempe, AZ 85281 Phone: 480-894-5550 Fax: 480-894-9469
Brent C. Sanders, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2501 E Southern Ave, 20, Tempe, AZ 85282 Phone: 480-969-3773 Fax: 480-969-3031

Michael David Guttenplan, MD - Medicare Otolaryngology in Tempe, AZ

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Study provides insights into molecular mechanisms of ZIKV infection

Despite international guidelines, wide variations exist in breast cancer care

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

Researchers highlight how biomarkers after ACL reconstruction may signal severity of PTOA later in life

UCB, Emerald BioStructures expand collaboration for structure-based drug discovery

Medicare Reassignments

Study provides insights into molecular mechanisms of ZIKV infection

Despite international guidelines, wide variations exist in breast cancer care

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

Researchers highlight how biomarkers after ACL reconstruction may signal severity of PTOA later in life

UCB, Emerald BioStructures expand collaboration for structure-based drug discovery

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Study provides insights into molecular mechanisms of ZIKV infection

Despite international guidelines, wide variations exist in breast cancer care

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

Researchers highlight how biomarkers after ACL reconstruction may signal severity of PTOA later in life

UCB, Emerald BioStructures expand collaboration for structure-based drug discovery

Otolaryngology Doctors in Tempe, AZ